| [1] |
Ruddy KJ, Winer EP. Male breast cancer: risk factors,biology, diagnosis, treatment, and survivorship [J]. Ann Oncol,2013,24(6):1434-1443.
|
| [2] |
Chavez-Macgregor M, Clarke CA, Lichtensztajn D,et al. Male breast cancer according to tumor subtype and race:a populationbased study[J].Cancer,2013,119(9):1611-1617.
|
| [3] |
Serarslan A, Gursel B, Okumus NO, et al. Male breast cancer: 20 years experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey [J]. Asian Pac J Cancer Prev,2015,16(15):6673-6679.
|
| [4] |
李林,朱明智,邱新光,等. 男性乳腺癌前哨淋巴结活检11 例分析[J].国际外科学杂志,2015,42(3):171-173.
|
| [5] |
Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer version 2.2015[J]. J Natl Compr Canc Netw,2015,13(4):448-475.
|
| [6] |
Sipetic-Grujicic SB, Murtezani ZH, Neskovic-Konstatinovic ZB, et al. Multivariate analysis of prognostic factors in male breast cancer in Serbia[J]. Asian Pac J Cancer Prev,2014,15(7):3233-3238.
|
| [7] |
宋健,李荣国,赵悦,等.男性乳腺癌的诊治现状[J].临床外科杂志,2014,22(10):787-789.
|
| [8] |
Nilsson C,Johansson I,Ahlin C,et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact[J].Acta Oncol,2013,52(1) :102-109.
|
| [9] |
Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment [J].Eur J Pharmacol,2013,717(1-3):71-83.
|
| [10] |
钟颖,孙强,周易冬,等. 晚期乳腺癌患者的内分泌治疗[J/CD].中华乳腺病杂志:电子版,2015,9(2):124-126.
|
| [11] |
Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men [J].Ann Intern Med,2002,137(5):678-687.
|
| [12] |
Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer[J].Breast Cancer Res Treat,2012,136(2):495-502.
|
| [13] |
Eggemann H,Ignatov A,Smith BJ,et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients[J]. Breast Cancer Res Treat,2013,137(2):465-470.
|
| [14] |
刘朋,王芙荣,纪立伟,等.212 例他莫昔芬不良反应回顾性分析[J].中国药物应用与监测,2011,8(6):366-368.
|
| [15] |
Pemmaraju N, Munsell MF, Hortobagyi GN, et al.Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects[J]. Ann Oncol,2012,23(6):1471-1474.
|
| [16] |
Pritchard KI, Shepherd LE, Chapman JA, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14[J]. J Clin Oncol,2011,29(29):3869-3876.
|
| [17] |
Cardoso F, Bischoff J, Brain E, et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women[J]. Cancer Treat Rev,2013,39(5):457-465.
|
| [18] |
Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients: biological and clinical implications[J]. Ann Oncol,2010,21(6):1243-1245.
|
| [19] |
Carmona-Bayonas A. Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer[J].Breast,2007,16(3):323-325.
|
| [20] |
陈峰,邱丽贞.芳香化酶抑制剂在早期男性乳腺癌治疗中的生物学效益及临床意义[J]. 中国医学杂志,2014,94(4):273-275.
|
| [21] |
Zagouri F, Sergentanis TN, Koutoulidis V. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series[J].Br J Cancer,2013,108(11):2259-2263.
|
| [22] |
Zagouri F, Sergentanis TN, Azim HA Jr, et al. Aromatase inhibitors in male breast cancer: a pooled analysis [J]. Breast Cancer Res Treat,2015,151(1):141-147.
|
| [23] |
Di Lauro L, Vici P, Del Medico P, et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer [J]. Breast Cancer Res Treat,2013,14l(1):119-123.
|
| [24] |
Roselli CE, Resko JA. Sex differences in androgen-regulated expression of cytochrome P450 aromatase in the rat brain [J].J Steroid Biochem Mol Biol,1997,61(3-6):365-374.
|
| [25] |
Morisseau C, Pakhomova S, Hwang SH, et al. Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides[J].Bioorg Med Chem Lett,2013,23(13):3818-3821.
|
| [26] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg versus 250 mg in the randomized CONFIRM trial[J]. J Natl Cancer Inst,2014, 106 (1):djt337.
|
| [27] |
Kiluk JV, Lee MC, Park CK, et al. Male breast cancer:management and follow-up recommendations[J]. Breast J,2011,17(5):503-509.
|
| [28] |
Wenhui Z, Shuo L, Dabei T, et al. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment[J]. Eur J Endocrinol,2014,171(4):527-533.
|
| [29] |
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy [J]. N Engl J Med,2012,367(13):1187-1197.
|
| [30] |
Robinson JL, Macarthur S, Ross-Innes CS, et a1. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 [ J]. EMBO J, 2011, 30 (15):3019-3027.
|